Alembic Pharmaceuticals awarded EU GMP certificate

Pharmaceutical major Alembic Pharmaceuticals has received EU GMP certificate from the audit conducted between August 8 and 10, 2017 at its formulation facility at Panelav. As such, on the NSE the stock attracted a traded volume of 11,598 shares and traded value of Rs 60.93 lakhs. 
 
The company has a return on equity of 38.46%. On a yearly basis the company has lost 17.10% and has underperformed the BSE Mid-Cap index and BSE Healthcare index. Meanwhile, the BSE Healthcare index gained 2.07% at the 13,421 level. Dr. Reddy’s Lab is the top index gainer and majorly contributing to index gains.
  
Alembic Pharmaceuticals is engaged in developing formulations and active pharmaceutical ingredients (API). The company focuses on anti-infective, analgesic, and cough and cold therapies. 
 
Good manufacturing practice (GMP) describes the minimum standard that a medicine manufacturer must meet in its production processes. The European Medicines Agency (EMA) coordinates inspections to verify compliance with these standards and plays a key role in harmonising GMP activities at the European Union (EU) level.